ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

American Journal of Gastroenterology

Volumn 112, Issue 2, 2017, Pages 212-238

  Chey, William D ^a   Leontiadis, Grigorios I ^b   Howden, Colin W ^c   Moss, Steven F ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISMUTH; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; RIFABUTIN; ANTACID AGENT; ANTIINFECTIVE AGENT; METRONIDAZOLE; PROTON PUMP INHIBITOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ASYMPTOMATIC INFECTION; CANCER RISK; COMBINATION DRUG THERAPY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSPEPSIA; EARLY CANCER; ERADICATION THERAPY; EVIDENCE BASED PRACTICE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HIGH RISK POPULATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IRON DEFICIENCY ANEMIA; LOW DRUG DOSE; MARGINAL ZONE LYMPHOMA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; NORTH AMERICA; PATHOGEN CLEARANCE; PENICILLIN ALLERGY; PEPTIC ULCER; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; STOMACH CANCER; STOMACH MUCOSA; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; TREATMENT FAILURE;

AMOXICILLIN; ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BISMUTH; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITORS; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 85009186253     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.563     Document Type: Review

References (217)

1. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
2. Opekun AR, Gilger MA, Denyes SM et al. Helicobacter pylori infection in children of Texas. J Pediatr Gastroenterol Nutr 2000; 31: 405-10.
3. Parkinson AJ, Gold BD, Bulkow L et al. High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol 2000; 7: 885-8.
4. Malaty HM, El-Kasabany A, Graham DY et al. Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet 2002; 359: 931-5.
5. Sinha SK, Martin B, Gold BD et al. The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community and the potential for parent-to-child transmission. Helicobacter 2004; 9: 59-68.
6. Schwarz S, Morelli G, Kusecek B et al. Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog 2008; 4: e1000180.
7. Bruce MG, Maaroos HI. Epidemiology of Helicobacter pylori infection. Helicobacter 2008; 13 Suppl 1: 1-6.
8. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter 2014; 19 Suppl 1: 1-5.
9. Ford AC, Forman D, Bailey AG et al. Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a crosssectional study. Int J Epidemiol 2007; 36: 1327-33.
10. Weyermann M, Rothenbacher D, Brenner H. Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings. Am J Gastroenterol 2009; 104: 182-9.
11. Krumbiegel P, Lehmann I, Alfreider A et al. Helicobacter pylori determination in non-municipal drinking water and epidemiological fndings. Isotopes Environ Health Stud 2004; 40: 75-80
12. de Martel C, Parsonnet J. Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys. Dig Dis Sci 2006; 51: 2292-301.
13. Naja F, Kreiger N, Sullivan T. Helicobacter pylori infection in Ontario: prevalence and risk factors. Can J Gastroenterol 2007; 21: 501-6.
14. Nguyen T, Ramsey D, Graham D et al. The prevalence of Helicobacter pylori remains high in African American and Hispanic veterans. Helicobacter 2015; 20: 305-15.
15. Everhart JE, Kruszon-Moran D, Perez-Perez GI et al. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000; 181: 1359-63.
16. Epplein M, Cohen SS, Sonderman JS et al. Neighborhood socio-economic characteristics, African ancestry, and Helicobacter pylori sero-prevalence. Cancer Causes Control 2012; 23: 897-906
17. Epplein M, Signorello LB, Zheng W et al. Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev 2011; 20: 826-34.
18. Goodman KJ, Jacobson K, Veldhuyzen van Zanten S. Helicobacter pylori infection in Canadian and related Arctic Aboriginal populations. Can J Gastroenterol 2008; 22: 289-95.
19. Cardenas VM, Mena KD, Ortiz M et al. Hyperendemic H. pylori and tapeworm infections in a U.S.-Mexico border population. Pub Health Reports 2010; 125
20. Goodman KJ, O'Rourke K, Day RS et al. Helicobacter pylori infection in pregnant women from a U.S.-Mexico border population. J Immigr Health 2003; 5: 99-107.
21. Cheung J, Goodman KJ, Girgis S et al. Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns. BMJ Open 2014; 4: e003689.
22. Peleteiro B, Bastos A, Ferro A et al. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014; 59: 1698-709.
23. Siao D, Somsouk M. Helicobacter pylori: evidence-based review with a focus on immigrant populations. J Gen Intern Med 2014; 29: 520-8.
24. Perez-Perez GI, Olivares AZ, Foo FY et al. Seroprevalence of Helicobacter pylori in New York City populations originating in East Asia. J Urban Health 2005; 82: 510-6.
25. Tsai CJ, Perry S, Sanchez L et al. Helicobacter pylori infection in different generations of Hispanics in the San Francisco Bay Area. Am J Epidemiol 2005; 162: 351-7.
26. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
27. Leontiadis GI, Ford AC, Moayyedi P. Helicobacter pylori infection. BMJ Clinical Evidence 2009; 10: 0406.
28. Nakamura S, Sugiyama T, Matsumoto T et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-13.
29. Wundisch T, Dieckhoff P, Greene B et al. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology 2012; 143: 936-42. quiz e13-4.
30. Ferreri AJ, Govi S, Ponzoni M. The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach. Curr Opin Oncol 2013; 25: 470-9.
31. Bang CS, Baik GH, Shin IS et al. Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. J Korean Med Sci 2015; 30: 749-56.
32. Jung, da H, Kim JH, Chung HS et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoS One 2015; 10: e0124725.
33. Yoon SB, Park JM, Lim CH et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 2014; 19: 243-8.
34. Lee YC, Chiang TH, Chou CK et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016; 150: 1113-1124.e5.
35. Harvey RF, Lane JA, Nair P et al. Clinical trial: prolonged benefcial Effect of Helicobacter pylori eradication on dyspepsia consultations-the Bristol Helicobacter Project. Aliment Pharmacol Ther 2010; 32: 394-400.
36. Delaney B, Ford AC, Forman D et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2005; (4): CD001961.
37. Ford AC, Moayyedi P, Jarbol DE et al. Meta-analysis: Helicobacter pylori'test and treat' compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther 2008; 28: 534-44.
38. Ford AC, Qume M, Moayyedi P et al. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data metaanalysis. Gastroenterology 2005; 128: 1838-44.
39. Moayyedi P, Soo S, Deeks J et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;(2):CD002096.
40. Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 168-74.
41. Stanghellini V, Chan FK, Hasler WL et al. Gastroduodenal disorders. Gastroenterology 2016; 150: 1380-92.
42. Yang YX, Brill J, Krishnan P et al. American Gastroenterological Association Institute Guideline on the role of upper gastrointestinal biopsy to evaluate dyspepsia in the adult patient in the absence of visible mucosal lesions. Gastroenterology 2015; 149: 1082-7.
43. Moayyedi P. American College of Gastroenterology and Candian Association of Gastroenterology guidelines on the management of dyspepsia. Am J Gastroenterol 2017 (in press).
44. Hong SJ, Kim SW. Helicobacter pylori infection in gastroesophageal reflux disease in the Asian Countries. Gastroenterol Res Pract 2015; 2015: 985249.
45. Gatenby P, Soon Y. Barrett's oesophagus: evidence from the current metaanalyses. World J Gastrointest Pathophysiol 2014; 5: 178-87.
46. Vakil N, Talley NJ, Stolte M et al. Patterns of gastritis and the Effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2006; 24: 55-63
47. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97: 2992-7.
48. Harvey RF, Lane JA, Murray LJ et al. Randomised controlled trial of Effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. Bmj 2004; 328: 1417.
49. Raghunath AS, Hungin AP, Wooff D et al. Systematic review: the Effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004; 20: 733-44.
50. Pilotto A, Perri F, Leandro G et al. Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study. Gerontology 2006; 52: 99-106.
51. Schwizer W, Menne D, Schutze K et al. The Effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study. United European Gastroenterol J 2013; 1: 226-35.
52. Xue Y, Zhou LY, Lin SR et al. Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study. Chin Med J (Engl) 2015; 128: 995-9.
53. Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
54. Moayyedi P, Wason C, Peacock R et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5: 206-14.
55. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
56. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-17.
57. Lanas A, Fuentes J, Benito R et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-86.
58. Stack WA, Atherton JC, Hawkey GM et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002; 16: 497-506.
59. Yeomans ND, Lanas AI, Talley NJ et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801.
60. Chan FK, Ching JY, Suen BY et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144: 528-35.
61. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010; 105: 2533-49.
62. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a metaanalysis. Lancet 2002; 359: 14-22.
63. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAIDrelated ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
64. Chan FK, Sung JJ, Chung SC et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-9.
65. Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with nonsteroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
66. Vergara M, Catalan M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411-8.
67. Leontiadis GI, Sreedharan A, Dorward S et al. Systematic reviews of the clinical Effectiveness and cost-Effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007; 11: iii-iv 1-164.
68. Lai KC, Lau CS, Ip WY et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003; 17: 799-805.
69. de Leest HT, Steen KS, Lems WF et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007; 12: 477-85.
70. Qu XH, Huang XL, Xiong P et al. Does Helicobacter pylori infection play a role in iron defciency anemia? A meta-analysis. World J Gastroenterol 2010; 16: 886-96.
71. Xia W, Zhang X, Wang J et al. Survey of anaemia and Helicobacter pylori infection in adolescent girls in Suihua, China and enhancement of iron intervention Effects by H. pylori eradication. Br J Nutr 2012; 108: 357-62.
72. Chen LH, Luo HS. Effects of H pylori therapy on erythrocytic and iron parameters in iron defciency anemia patients with H pylori-positive chronic gastristis. World J Gastroenterol 2007; 13: 5380-3.
73. Yuan W, Li Y, Yang K et al. Iron defciency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665-76.
74. Sakai K, Koichi F, Sozu T et al. Eradication of Helicobacter pylori for iron defciency. Cochrane Database of Systematic Reviews 2015; (1): CD011480.
75. Jackson S, Beck PL, Pineo GF et al. Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol 2005; 78: 142-50.
76. Suzuki T, Matsushima M, Masui A et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol 2005; 100: 1265-70.
77. Tsutsumi Y, Kanamori H, Yamato H et al. Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann Hematol 2005; 84: 807-11.
78. Jaing TH, Yang CP, Hung IJ et al. Efcacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. Acta Paediatr 2003; 92: 1153-7.
79. Stasi R, Sarpatwari A, Segal JB et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113: 1231-40.
80. Neunert C, Lim W, Crowther M et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-207.
81. Wang J, Xu L, Shi R et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83: 253-60.
82. Ford AC, Forman D, Hunt RH et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014; 348: g3174.
83. Leontiadis GI, Sharma VK, Howden CW. Non-gastrointestinal tract associations of Helicobacter pylori infection. Arch Intern Med 1999; 159: 925-40.
84. Madisch A, Miehlke S, Neuber F et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy-a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther 2006; 23: 473-9.
85. Ji F, Wang ZW, Ning JW et al. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. World J Gastroenterol 2006; 12: 1770-3.
86. Schulz C, Schutte K, Malfertheiner P. Does H. pylori eradication therapy beneft patients with hepatic encephalopathy?: systematic review. J Clin Gastroenterol 2014; 48: 491-9.
87. Li L, Li L, Zhou X. Helicobacter pylori infection is associated with an increased risk of hyperemesis gravidarum: a meta-analysis. Gastroenterol Res Pract 2015; 2015: 278905.
88. Budzynski J, Kozinski M, Klopocka M et al. Clinical signifcance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. Clin Res Cardiol 2014; 103: 855-86.
89. Rees K, Stowe R, Patel S et al. Helicobacter pylori eradication for Parkinson's disease. Cochrane Database Syst Rev 2011; (11): CD008453.
90. Shakouri A, Compalati E, Lang DM et al. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the grading of recommendations assessment, development, and evaluation system. Curr Opin Allergy Clin Immunol 2010; 10: 362-9.
91. Dai YN, Yu WL, Zhu HT et al. Is Helicobacter pylori infection associated with glycemic control in diabetics? World J Gastroenterol 2015; 21: 5407-16.
92. Lender N, Talley NJ, Enck P et al. Review article: associations between Helicobacter pylori and obesity-an ecological study. Aliment Pharmacol Ther 2014; 40: 24-31.
93. McCune A, Lane A, Murray L et al. Reduced risk of atopic disorders in adults with Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2003; 15: 637-40.
94. Taye B, Enquselassie F, Tsegaye A et al. Is Helicobacter pylori infection inversely associated with atopy? A systematic review and meta-analysis. Clin Exp Allergy 2015; 45: 882-90.
95. Dellon ES, Peery AF, Shaheen NJ et al. Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology 2011; 141: 1586-92.
96. Elitsur Y, Alrazzak BA, Preston D et al. Does Helicobacter pylori protect against eosinophilic esophagitis in children? Helicobacter 2014; 19: 367-71.
97. Furuta K, Adachi K, Aimi M et al. Case-control study of association of eosinophilic gastrointestinal disorders with Helicobacter pylori infection in Japan. J Clin Biochem Nutr 2013; 53: 60-2.
98. Ronkainen J, Talley NJ, Aro P et al. Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut 2007; 56: 615-20.
99. von Armin U, Wex T, Link A et al. Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis. Aliment Pharmacol Ther 2016; 43: 825-30.
100. Van Zanten SV, Aplin L, Chang H-J et al. Su1198 Community H. pylori Project Treatment Trial results from the Canadian Arctic. Gastroenterology 2014; 146: S-400.
101. Lebwohl B, Blaser MJ, Ludvigsson JF et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol 2013; 178: 1721-30.
102. Rokkas T, Gisbert JP, Niv Y et al. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterol J 2015; 3: 539-50.
103. Li BZ, Treapleton DE, Wang JY et al. Comparative Effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015; 351: h4052.
104. Coss E, Geta RM, Dunbar KB et al. Sequential therapy is not better at eradication of primary Helicobacter pylori infection when compared to standard triple therapy in the United States-a prospective, randomized evaluation in a United States population. Gastroenterology 2014; 146: S-399.
105. Fallone CA, Barkun AN, Szilagyi A et al. Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada. Can J Gastroenterol 2013; 27: 397-402.
106. Basu PP, Rayapudi K, Pacana T et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106: 1970-5.
107. Chen YK, Jajodia P, DeGuzman L et al. Randomized controlled trial comparing proton pump inhibitor-based eradication regimens versus low-cost eradication regimen for patients with Helicobacter pylori with uninvestigated dyspepsia. J App Res 2006; 6: 214-22.
108. Vakil N, Lanza F, Schwartz H et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107.
109. Bochenek WJ, Peters S, Fraga PD et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter 2003; 8: 626-42.
110. Veldhuyzen van Zanten S, Fedorak RN, Lambert J et al. Absence of symptomatic beneft of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol 2003; 98: 1963-9.
111. Lara LF, Cisneros G, Gurney M et al. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med 2003; 163: 2079-84.
112. Laine L, Hunt R, El-Zimaity H et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-7.
113. Sullivan B, Coyle W, Nemec R et al. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol 2002; 97: 2536-9.
114. Chiba N, Van Zanten SJ, Sinclair P et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. Bmj 2002; 324: 1012-6.
115. Stevens VJ, Shneidman RJ, Johnson RE et al. Helicobacter pylori eradication in dyspeptic primary care patients: a randomized controlled trial of a pharmacy intervention. West J Med 2002; 176: 92-6.
116. Bardhan K, Bayerdorffer E, Veldhuyzen Van Zanten SJ et al. The HOMER Study: the Effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000; 5: 196-201.
117. Veldhuyzen Van Zanten S, Lauritsen K, Delchier JC et al. One-week triple therapy with esomeprazole provides Effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 1605-11.
118. Veldhuyzen Van Zanten S, Farley A, Marcon N et al. Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study. Can J Gastroenterol 2000; 14: 599-602.
119. Laine L, Fennerty MB, Osato M et al. Esomeprazole-based Helicobacter pylori eradication therapy and the Effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000; 95: 3393-8.
120. Yuan Y, Ford AC, Khan KJ et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
121. Luther J, Higgins PD, Schoenfeld PS et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efcacy and tolerability. Am J Gastroenterol 2010; 105: 65-73.
122. Shiota S, Reddy R, Alsarraj A et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 2015; 13: 1616-24.
123. McMahon BJ, Hennessy TW, Bensler JM et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139: 463-9.
124. Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
125. McNulty CA, Lasseter G, Shaw I et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 2012; 35: 1221-30.
126. Lim SG, Park RW, Shin SJ et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis 2016; 48: 385-90.
127. Venerito M, Krieger T, Ecker T et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88: 33-45.
128. Treiber G, Ammon S, Schneider E et al. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998; 3: 54-8.
129. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34.
130. Gatta L, Vakil N, Vaira D et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. Bmj 2013; 347: f4587.
131. Greenberg ER, Anderson GL, Morgan DR et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507-14.
132. Zullo A, Rinaldi V, Winn S et al. A new highly Effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 715-8.
133. Gatta L, Vakil N, Leandro G et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-79, quiz 1080.
134. Liou JM, Chen CC, Chen MJ et al. Sequential versus triple therapy for the frst-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-13.
135. Hsu PI, Wu DC, Wu JY et al. Modifed sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the fnal 7 days. Helicobacter 2011; 16: 139-45.
136. Wang B, Wang YH, Lv ZF et al. Review: efcacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and metaanalysis. Helicobacter 2015; 20: 79-88.
137. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015; 54: 703-10.
138. Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based frst-line therapy versus standard frst-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One 2014; 9: e85620.
139. Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for frst-line eradication of Helicobacter pylori? A systematic review and meta-analysis. Scand J Gastroenterol 2014; 49: 528-38.
140. Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone sequential therapy for Helicobacter pylori: a meta-analysis. Pharmacotherapy 2015; 35: 719-30.
141. Tveit AH, Bruce MG, Bruden DL et al. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol 2011; 49: 3638-43.
142. Eng NF, Ybazeta G, Chapman K et al. Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario. Can J Infect Dis Med Microbiol 2015; 26: 137-44.
143. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efcacy and safety of Lactobacillus-containing and Bifdobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013; 47: 25-32.
144. Zhang MM, Qian W, Qin YY et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World Journal of Gastroenterology 2015; 21: 4345-57.
145. Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
146. Buring SM, Winner LH, Hatton RC et al. Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis. Pharmacotherapy 1999; 19: 324-32.
147. Lee M, Kemp JA, Canning A et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999; 159: 2312-6.
148. Tang HL, Li Y, Hu YF et al. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013; 8: e62162.
149. Suzuki T, Matsuo K, Ito H et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217-24.
150. Horikawa C, Kodama S, Fujihara K et al. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2014; 106: 81-7.
151. Dore MP, Leandro G, Realdi G et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 68-76.
152. Fischbach L, Evans EL. Meta-analysis: the Effect of antibiotic resistance status on the efcacy of triple and quadruple frst-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-57.
153. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86 e3, Discussion e12-3.
154. Kuo CH, Hu HM, Kuo FC et al. Efcacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009; 63: 1017-24.
155. Perna F, Zullo A, Ricci C et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007; 39: 1001-5.
156. Smith SM, O'Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 2014; 20: 9912-21.
157. Camargo MC, Garcia A, Riquelme A et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014; 109: 485-95.
158. Tung I, Aramin H, Vavinskaya V et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514-33.
159. Duck WM, Sobel J, Pruckler JM et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10: 1088-94.
160. Hicks LA, Taylor TH Jr., Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med 2013; 368: 1461-2.
161. Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci 2014; 1: 19.
162. Lopez-Gongora S, Puig I, Calvet X et al. Systematic review and metaanalysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother 2015; 70: 2447-55.
163. Fiorini G, Vakil N, Zullo A et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013; 11: 507-10.
164. Liou JM, Chen CC, Chang CY et al. Efcacy of genotypic resistanceguided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450-6.
165. McNicholl AG, Gasbarrini A, Tepes B et al. Pan-European Registry on H. pylori Management (HP-EuReg): Bacterial Resistance. Gastroenterology 2015; 148: S-417.
166. Chey WD, Metz DC, Shaw S et al. Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 1171-4.
167. Laine L, Estrada R, Trujillo M et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998; 129: 547-50.
168. Ofman J, Wallace J, Badamgarav E et al. The cost-Effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage. Am J Gastroenterol 2002; 97: 1941-50.
169. Pohl H, Finlayson SR, Sonnenberg A et al. Helicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment? Aliment Pharmacol Ther 2005; 22: 529-37.
170. Gene E, Calvet X, Azagra R. Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers-a cost-Effectiveness analysis. Aliment Pharmacol Ther 2000; 14: 433-42.
171. Navarro-Jarabo JM, Fernandez N, Sousa FL et al. Efcacy of rifabutinbased triple therapy as second-line treatment to eradicate Helicobacter pylori infection. BMC Gastroenterol 2007; 7: 31.
172. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843-61.
173. Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289-94.
174. Lee SK, Lee SW, Park JY et al. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Helicobacter 2011; 16: 410-4.
175. Mantzaris GJ, Petraki C, Petraki K et al. Prospective, randomized study of seven versus fourteen days omeprazole quadruple therapy for eradication of Helicobacter pylori infection in patients with duodenal ulcer after failure of omeprazole triple therapy. Ann Gastroenterol 2005; 18: 330-5.
176. Nista EC, Candelli M, Cremonini F et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003; 18: 627-33.
177. Magaret N, Burm M, Faigel D et al. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis 2001; 19: 174-8.
178. Miehlke S, Kirsch C, Schneider-Brachert W et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8: 310-9.
179. Cao Z, Chen Q, Zhang W et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol 2015; 50: 1185-90.
180. Kim MS, Kim N, Kim SE et al. Long-term follow up Helicobacter pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC Gastroenterol 2013; 13: 138.
181. Chuah SK, Tai WC, Hsu PI et al. The efcacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/protonpump inhibitor treatment-a pilot study. Helicobacter 2012; 17: 374-81.
182. Lee BH, Kim N, Hwang TJ et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: Effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38-45
183. Uygun A, Ozel AM, Yildiz O et al. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard frst-line therapy. J Gastroenterol Hepatol 2008; 23: 42-5.
184. Kang JM, Kim N, Lee DH et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 2007; 12: 623-8.
185. Bilardi C, Dulbecco P, Zentilin P et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004; 2: 997-1002.
186. Di Caro S, Franceschi F, Mariani A et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009; 41: 480-5.
187. Karatapanis SS, Skorda L, Georgopoulos S et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection. Annals of Gastroenterology 2009; 22: 263-7.
188. Gisbert JP. Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 1484-6.
189. Ercin CN, Uygun A, Toros AB et al. Comparison of 7-and 14-day frstline therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turk J Gastroenterol 2010; 21: 12-16.
190. Cheng HC, Chang WL, Chen WY et al. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter 2007; 12: 359-63.
191. Gisbert JP, Barrio J, Modolell I et al. Helicobacter pylori frst-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci 2015; 60: 458-64.
192. Furuta T, Sugimoto M, Yamade M et al. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. Intern Med 2014; 53: 571-5.
193. Ueki N, Miyake K, Kusunoki M et al. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing tripletherapy failure. Helicobacter 2009; 14: 91-9.
194. Jheng GH, Wu IC, Shih HY et al. Comparison of second-line quadruple therapies with or without bismuth for Helicobacter pylori infection. Biomed Res Int 2015; 2015: 163960.
195. Hori K, Miwa H, Matsumoto T. Efcacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the japanese population. Helicobacter 2011; 16: 234-40.
196. Molina-Infante J, Romano M, Fernandez-Bermejo M et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-128.e1.
197. Wu DC, Hsu PI, Wu JY et al. Sequential and concomitant therapy with four drugs is equally Effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41.e1.
198. Peitz U, Sulliga M, Wolle K et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002; 16: 315-24.
199. Lamouliatte H, Megraud F, Delchier JC et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003; 18: 791-7.
200. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209-21.
201. Liu X, Wang H, Lv Z et al. Rescue therapy with a proton pump inhibitor plus amoxicillin and rifabutin for Helicobacter pylori infection: a systematic review and meta-analysis. Gastroenterol Res Pract 2015; 2015: 415648.
202. Lim HC, Lee YJ, An B et al. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter 2014; 19: 455-61.
203. Miehlke S, Hansky K, Schneider-Brachert W et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006; 24: 395-403.
204. Perri F, Festa V, Clemente R et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58-62.
205. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol 2001; 15: 413-31.
206. Yang JC, Lin CJ, Wang HL et al. High-dose dual therapy is superior to standard frst-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015; 13: 895-905.e5.
207. Nishizawa T, Suzuki H, Nakagawa I et al. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J Gastroenterol Hepatol 2008; 23: S167-S170.
208. Murakami K, Furuta T, Ando T et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol 2013; 48: 1128-35.
209. Shirai N, Sugimoto M, Kodaira C et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007; 63: 743-9.
210. Kim SB, Lee SH, Kim KO et al. [Ten-day sequential therapy versus bismuth based quadruple therapy as second line treatment for Helicobacter pylori infection]. Korean J Gastroenterol 2015; 66: 261-7.
211. Isakov V, Domareva I, Koudryavtseva L et al. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002; 16: 1277-82.
212. Qasim A, Sebastian S, Tornton O et al. Rifabutin-and furazolidonebased Helicobacter pylori eradication therapies after failure of standard frst-and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 91-6.
213. Tay CY, Windsor HM, Tirriot F et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther 2012; 36: 1076-83.
214. Macy E. Penicillin allergy: optimizing diagnostic protocols, public health implications, and future research needs. Curr Opin Allergy Clin Immunol 2015; 15: 308-13.
215. Fallone CA, Chiba N, van Zanten SV et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151: 51-69.e14.
216. Blanchard TG, Czinn SJ. Current status and prospects for a Helicobacter pylori vaccine. Gastroenterol Clin North Am 2015; 44: 677-89.
217. Zeng M, Mao XH, Li JX et al. Efcacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1457-64.